MADALYN QUALIZZA: Open Payments
NPI 1962163691 · DYER, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$631 in 26 payments from 19 companies in 2025. Trend: 2023 $325 · 2024 $403 · 2025 $631
Food & beverage: $631
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 3 | $75 |
| AstraZeneca Pharmaceuticals LP | 3 | $58 |
| Incyte Corporation | 2 | $50 |
| Novartis Pharmaceuticals Corporation | 2 | $45 |
| Merck Sharp & Dohme LLC | 2 | $42 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $36 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $35 |
| BeOne Medicines USA, Inc. | 1 | $34 |
| Syndax Pharmaceuticals, Inc. | 1 | $34 |
| JAZZ PHARMACEUTICALS INC. | 1 | $29 |
Products named: SCEMBLIX, KEYTRUDA, ICLUSIG, TEVIMBRA, EPKINLY, ELAHERE, ZEPZELCA, JAKAFI.
Industry payments across IN — which companies pay providers there.
